Andrew Walker

Dr. Andrew Walker

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2016 in Canadian Respiratory Journal
Verified
Journal Article
Open access
PDF file
KYKevin F. Yee
Kevin F. Yee
AWAndrew Walker
Andrew Walker
EGElaine Gilfoyle
Elaine Gilfoyle
Objective. There is increasing evidence of adverse outcomes associated with blood transfusions for adult traumatic brain injury patients. However, current evidence suggests that pediatric traumatic brain injury patients may respond to blood transfusions differently on a vascular level. This study examined the influence of blood transfusions and anemia on the outcome of pediatric traumatic brain injury patients.Design. A retrospective cohort analysis of severe pediatric traumatic brain injury (TBI) patients was undertaken to investigate the association between blood transfusions and anemia on patient outcomes.Measurements and Main Results. One hundred and twenty patients with severe traumatic brain injury were identified and included in the analysis. The median Glasgow Coma Scale (GCS) was 6 and the mean hemoglobin (Hgb) on admission was 115.8 g/L. Forty-three percent of patients (43%) received at least one blood transfusion and the mean hemoglobin before transfusion was 80.1 g/L. Multivariable regression analysis revealed that anemia and the administration of packed red blood cells were not associated with adverse outcomes. Factors that were significantly associated with mortality were presence of abusive head trauma, increasing PRISM score, and low GCS after admission.Conclusion. In this single centre retrospective cohort study, there was no association found between anemia, blood transfusions, and hospital mortality in a pediatric traumatic brain injury patient population.

1 April 2019 in Journal of Critical Care
Verified
Journal Article
Closed access
DGDailys Garcia-Jorda
Dailys Garcia-Jorda
AWAndrew Walker
Andrew Walker
JCJenna Camphaug
Jenna Camphaug
WBWendy Bissett
Wendy Bissett
TSTanya Spence
Tanya Spence
EGElaine Gilfoyle
Elaine Gilfoyle

15 July 2023 in Children
Verified
Journal Article
Open access
PDF file
RLRob D Long
Rob D Long
AWAndrew Walker
Andrew Walker
SPSi Chen Pan
Si Chen Pan
JMJillian Miller
Jillian Miller
LRLaura Rayner
Laura Rayner
NRNivez Rasic
Nivez Rasic
Background: More could be known about baseline factors related to desirable Intensive Interdisciplinary Pain Treatment (IIPT) outcomes. This study examined how baseline characteristics (age, gender, child pain catastrophizing (PCS-C), pain interference, pain intensity, anxiety, depression, paediatric health-related quality of life (PedsQLTM), and parent catastrophizing (PCS-P)) were associated with discharge and 3-month follow-up scores of PCS-C, pain intensity, and pain interference. Methods: PCS-C, pain intensity, and pain interference T-scores were acquired in 45 IIPT patients aged 12–18 at intake (baseline), discharge, and 3-month follow-up. Using available and imputed data, linear mixed models were developed to explore associations between PCS-C, pain intensity, and pain interference aggregated scores at discharge and follow-up with baseline demographics and a priori selected baseline measures of pain, depression, anxiety, and PCS-C/P. Results: PCS-C and pain interference scores decreased over time compared to baseline. Pain intensity did not change significantly. Baseline PCS-C, pain interference, anxiety, depression, and PedsQLTM were associated with discharge/follow-up PCS-C (available and imputed data) and pain interference scores (available data). Only baseline pain intensity was significantly associated with itself at discharge/follow-up. Conclusions: Participants who completed the IIPT program presented with reduced PCS-C and pain interference over time. Interventions that target pre-treatment anxiety and depression may optimize IIPT outcomes.

1 August 2020 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
CYChristopher D. Young
Christopher D. Young
AWAndrew Walker
Andrew Walker
BWBryce A. Weber
Bryce A. Weber
ASAdam O. Spencer
Adam O. Spencer

1 January 2010
Verified
Conference Paper
Closed access
PDF file
AWAndrew Walker
Andrew Walker
KLKogan Lee
Kogan Lee
KRKristina D. Rinker
Kristina D. Rinker
RSRobert D. Shepherd
Robert D. Shepherd
GDGary M. Dobson
Gary M. Dobson
CJClifton R. Johnston
Clifton R. Johnston
The intravenous fluid of choice for acute blood volume replacement remains controversial. We focus here on the two hydroxyethyl (HES) available in Canada: HES 130/0.40 (Voluven®) and HES 260/0.45 (Pentaspan®). Although information regarding their pharmacokinetic and risk/benefit profiles are available, how the infusion of these fluids could affect blood viscosity and vascular endothelial function in humans is largely unknown. Dynamic viscosity was measured at 21°C and 37°C through capillary viscometry. The HES solutions were driven through a closed flow loop at room temperature (21°C). Viscosity at 21°C was 7.62 centipoise (cP) for HES 260/0.45 and 2.73 cP for HES 130/0.40 decreasing to 4.23 cP for HES 260/0.45 and 1.72 cP for HES 130/0.40 at 37°C. Analysis of viscous behaviour through pipe flow found that HES 260/0.45 displayed marginal variations in viscosity suggesting Newtonian behaviour across our range of Re measured. HES 130/0.40 displayed an appreciable increase in viscosity at higher Re suggesting the presence of shear thickening behaviour. Human aortic endothelial cells (HAEC) and human microvascular endothelial cells (HMVEC) were exposed to the HES solutions and saline to identify chemical effects on vascular endothelium. Western blot quantification showed that E-selectin was the leukocyte adhesion receptor that was most strongly affected, and this was not dose dependent. Interestingly, HAEC and HMVEC had different responses to HES treatment, suggesting that different vascular tissues may have different outcomes to HES infusion. Protein expression in HMVEC decreased when exposed to both HES solutions.

14 September 2026 in American Journal of Perinatology
Verified
Journal Article
Closed access
MGMarika K. Grant
Marika K. Grant
JFJoanna J. Fifen
Joanna J. Fifen
AWAndrew Walker
Andrew Walker
ABAmina A. Benlamri
Amina A. Benlamri
STSelphee Tang
Selphee Tang
ALAbhay Lodha
Abhay Lodha
In 2016, the US Food and Drug Administration (FDA) warned that general anesthetics and sedative agents in children younger than 3 years may impair neurodevelopment. Very preterm infants could be especially vulnerable because of brain immaturity. We examined the association between the number of US FDA-warned anesthetic and sedative agents and full-scale intelligence quotient (FSIQ) at age 3 years in infants born < 29 weeks' gestational age (GA). In this retrospective study, all infants born (< 29 weeks' gestation) between January 2006 and December 2012 were evaluated for exposure to FDA-warned anesthetic and sedative agents from birth through 45 weeks' postconceptual age. The agents included volatile anesthetics, propofol, benzodiazepines, ketamine, chloral hydrate, and barbiturates. Exposure count was defined by the number of different agents administered: 1 exposure (1 agent); 2 exposures (2 agents); and ≥ 3 exposures (≥ 3 agents), irrespective of the number of procedures. We analyzed the association between FSIQ and exposure count using imputed and complete case univariable and multivariable linear regressions adjusted for neonatal and maternal factors. Of 650 eligible infants, 435 (67%) had FSIQ assessed at 3 years. Imputed adjusted associations (95% confidence interval, p-value) between FSIQ and exposure to 1, 2, or ≥ 3 different agents were − 3 (− 7 to 2, p = 0.284), − 4 (− 9 to 1, p = 0.101), and − 7 (− 15 to 1, p = 0.079) points, respectively. Exposure to 1, 2, or ≥ 3 different FDA-warned anesthetic and sedative agents (volatile anesthetics, propofol, benzodiazepines, barbiturates, and ketamine) in very preterm infants born < 29 weeks' GA was not associated with a clinically meaningful decrease in FSIQ points at 36 months' corrected age.